These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27846368)

  • 1. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.
    Schiffmann I; Greve G; Jung M; Lübbert M
    Epigenetics; 2016 Dec; 11(12):858-870. PubMed ID: 27846368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA methyltransferases in non-small-cell lung cancer.
    Al-Yozbaki M; Jabre I; Syed NH; Wilson CM
    Semin Cancer Biol; 2022 Aug; 83():77-87. PubMed ID: 33486076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
    Vendetti FP; Rudin CM
    Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic-based therapies in cancer: progress to date.
    Song SH; Han SW; Bang YJ
    Drugs; 2011 Dec; 71(18):2391-403. PubMed ID: 22141383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review-Epigenetic therapy for cancer.
    Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
    Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
    Chistiakov DA; Orekhov AN; Bobryshev YV
    Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epigenetic DNA and histone modifications to treat kidney disease.
    Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
    Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets.
    Bajbouj K; Al-Ali A; Ramakrishnan RK; Saber-Ayad M; Hamid Q
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenomes as therapeutic targets.
    Hamm CA; Costa FF
    Pharmacol Ther; 2015 Jul; 151():72-86. PubMed ID: 25797698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer.
    Luo H; Shan J; Zhang H; Song G; Li Q; Xu CX
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):960-970. PubMed ID: 35189321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
    Kumar A; Emdad L; Fisher PB; Das SK
    Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer.
    Baird AM; Leonard J; Naicker KM; Kilmartin L; O'Byrne KJ; Gray SG
    Lung Cancer; 2013 Jan; 79(1):83-90. PubMed ID: 23116756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
    Ahuja N; Sharma AR; Baylin SB
    Annu Rev Med; 2016; 67():73-89. PubMed ID: 26768237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
    Cantor JP; Iliopoulos D; Rao AS; Druck T; Semba S; Han SY; McCorkell KA; Lakshman TV; Collins JE; Wachsberger P; Friedberg JS; Huebner K
    Int J Cancer; 2007 Jan; 120(1):24-31. PubMed ID: 17019711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging epigenetic targets and therapies in cancer medicine.
    Popovic R; Licht JD
    Cancer Discov; 2012 May; 2(5):405-13. PubMed ID: 22588878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Treatment Options in Urothelial Carcinoma.
    Pinkerneil M; Hoffmann MJ; Niegisch G
    Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics and therapeutic targets in gastrointestinal malignancies.
    Nagaraju GP; Kasa P; Dariya B; Surepalli N; Peela S; Ahmad S
    Drug Discov Today; 2021 Oct; 26(10):2303-2314. PubMed ID: 33895313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.